2 Dividend Stocks to Double Up On Right Now

Coca‑Cola reported Q3 revenue up 5% year‑over‑year to $12.5 billion with unit case volume +1% and adjusted EPS +6% to $0.82, gained share in non‑alcoholic ready‑to‑drink and remains a 63‑year Dividend King. Amgen posted Q3 revenue up 12% to $9.6 billion as growth from Repatha, Tezspire and newly launched biosimilar Pavblu ($213 million in the period) helped offset looming denosumab biosimilar erosion (denosumab = $6.6 billion in 2024, ~20% of sales); the company also has late‑stage pipeline assets (MariTide phase 3 program, bemarituzumab) supporting forward growth and continued dividend increases. These results reinforce defensive consumer and biotech fundamentals while highlighting tariff exposure for multinationals and IP/patent risk in biotech.

Analysis

Market structure: Coca‑Cola (KO) and Amgen (AMGN) are clear near‑term winners — KO benefits from resilient demand, local manufacturing and pricing power (KO reported $12.5bn revenue, +5% y/y) while AMGN is offsetting a ~20% revenue concentration risk (denosumab $6.6bn) with 12% y/y top‑line growth and biosimilar/Pavblu traction. Losers include originator exposure to biosimilars (Regeneron/REGN around Eylea) and smaller beverage players who lack scale to absorb commodity/tariff shocks. Across assets, KO outperformance supports lower credit spreads in staples and compresses equity volatility; AMGN dynamics lift biotech IV but may increase correlation with small‑cap biosimilar peers; aluminum/sugar and USD moves are key cross‑asset drivers.

Risk assessment: Tail risks include rapid biosimilar uptake driving >10–15% EPS shock to AMGN within 12 months, regulatory setbacks on late‑stage assets (Maritide Phase‑3 surprises), and a commodity/tariff shock that squeezes KO margins by 200+ bps. Immediate (days) effects are IV and FX swings; short term (weeks–months) are re‑rating around quarterly flows; long term (12–36 months) depends on pipeline approvals and structural market‑share shifts. Hidden dependency: faster payor/adoption cycles for biosimilars can compress pricing faster than clinical readouts predict.

Trade implications: Tactical: establish a core long in KO for income and defensive beta, and a hedged accumulation in AMGN to play pipeline + biosimilars. Use pair trades to monetize competitive displacement (long AMGN / short REGN) over 12–24 months. Options: write 3–6 month covered calls on KO to boost yield; for AMGN buy 9–12 month 5–15% OTM call spreads and/or buy 6‑month 10% OTM puts as protection. Reassess after two consecutive quarters of negative unit case volume (KO) or if AMGN non‑denosumab growth falls below +5% y/y.

Contrarian angles: Consensus likely underestimates KO margin sensitivity to concentrated input shocks and overestimates immediate pipeline replacement for AMGN’s denosumab revenue. Mispricing opportunities: market may be underpaying AMGN’s biosimilar commercial skill (Pavblu $213m initial sales) — if Pavblu or Repatha growth accelerates >50% q/q, upside can be front‑loaded. Historical parallel: branded leaders that diversified post‑patent cliff (e.g., Pfizer post‑Lipitor) recovered via M&A, buybacks and new launches; failure mode is slow adoption of biosimilars or regulatory holdouts for new assets.

Key Decisions for Investors

• Establish a 2–3% long position in Coca‑Cola (KO) over a 6–12 month horizon as a defensive income core; implement 3–6 month covered calls ~4–6% OTM to enhance yield and trim if unit case volume declines >2% y/y for two consecutive quarters.
• Initiate a 1.5–2% long position in Amgen (AMGN) as a 12–24 month growth/biotech hybrid, hedged with a 6‑month 10% OTM protective put (buy puts) sized to limit downside to ~1% portfolio risk; add a 9–12 month 5–15% OTM call spread (smaller notional) to capture pipeline upside.
• Enter a pair trade: long AMGN (1.5%) / short REGN (1.0%) over 12–24 months to monetize biosimilar displacement risk to Eylea; unwind if AMGN market share gains for Pavblu <5% after 12 months or if REGN reports >5% revenue upside from new launches.
• Rotate 3–5% of cyclical equity exposure into Consumer Staples (KO) and Healthcare (AMGN/large cap biotech) over the next 4–8 weeks to reduce portfolio beta; reassess allocation after two quarterly earnings cycles and commodity price moves (sugar/aluminum >10% y/y).